Have any questions? 706-721-6582 or cts@augusta.edu
- Actuate 1901: Phase 2 study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3) inhibitor, as a single agent or combined with Ruxolitinib, in patients with myelofibrosis
Clinical Trial
Actuate 1901: Phase 2 study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3) inhibitor, as a single agent or combined with Ruxolitinib, in patients with myelofibrosis
This research study involves giving patients an investigational drug called 9-ING-41, either by itself or together with ruxolitinib, a drug approved for the treatment of myelofibrosis. We are running this study to see if by stopping the activity of GSK-3? using 9 ING-41, it may be possible to treat myelofibrosis by killing the cancer cells and/or reducing or clearing the fibrosis in the bone marrow and also to help Ruxolitinib become effective or regain its effectiveness in patients where it has stopped being effective or is not effective enough
Eligibility Criteria
- Male or female, aged 18 years or older Subjects with confirmed chronic myeloid leukemia (CML) Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures Is ineligible or unwilling to undergo stem cell transplantation at the time of study entry Is ineligible for, intolerant of, or not adequately responding to approved therapies for myelofibrosis Must not be receiving any other investigational product
RESEARCH. INNOVATION. DISCOVERY.